Inovio Pharmaceuticals, Inc. (INO)
| Market Cap | 2.27B |
| Revenue (ttm) | 2.11M |
| Net Income (ttm) | -179.73M |
| Shares Out | 165.36M |
| EPS (ttm) | -1.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $11.10 |
| Previous Close | $11.49 |
| Change ($) | -0.39 |
| Change (%) | -3.39% |
| Day's Open | 11.56 |
| Day's Range | 10.85 - 11.85 |
| Day's Volume | 12,264,315 |
| 52-Week Range | 3.83 - 33.79 |
On Monday, March 01, Inovio Pharmaceuticals (NASDAQ:INO) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.
Inovio (INO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Qiagen NV (NYSE: QGEN) and Inovio Pharmaceuticals Inc (NASDAQ: INO) expanded their partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic pro...
PLYMOUTH MEETING, Pa. and GERMANTOWN, Md. and HILDEN, Germany, Feb. 24, 2021 /PRNewswire/ -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today a...
Inovio (INO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
On Inovio's (INO) fourth-quarter earnings call, investor focus will be on updates on the company's progress with the development of its COVID-19 vaccine candidate, INO-4800.
This straggler in the vaccine race is still facing some struggles -- but there are a couple of bright spots.
Inovio Pharmaceuticals (INO) closed the most recent trading day at $13.84, moving -0.93% from the previous trading session.
Shares of coronavirus vaccine developer Inovio Pharmaceuticals Inc (NASDAQ: INO) were surging Friday after a vote of confidence from the Street. Bullish Analyst, Fund Stake Prop Up Stock: Opp...
An analyst is really bullish about the biotech stock.
One of the most common questions traders have about stocks is “Why Is It Moving?”. That's why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro.
Once a leader in the COVID-19 vaccine race, does this biotech have what it takes to deliver market-shattering returns?
Reddit investors are sure hyped up about shares of this biotech underdog. Should you be as well?
In less than several weeks, Inovio Pharmaceuticals (NASDAQ: INO) shares have advanced from $8.8 to $19, and the current price stands around $15. Inovio Pharmaceuticals has signed an agreement ...
Probably not, if you're investing for the long term.
Pessimists have piled into these companies, but that doesn't seem to be fazing millennial investors one bit.
INO is one of the most highly shorted biotechs and among the top 25 stocks in terms of short interest listed on the NASDAQ/AMEX/NYSE. INO has recently raised funds and is planning to start a p...
None of them outperformed the cryptocurrency in 2020, but that could change this year.
Some of the best cheap stocks for 2021 include chipmakers like UMC stock and pharmaceuticals in the COVID-19 vaccine race such as INO stock. The post 7 Great Cheap Stocks To Buy For Solid Grow...
PLYMOUTH MEETING, Pa., Jan. 25, 2021 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat...
All four biotechs announced the pricing of stock offerings.
Shares of Inovio Pharmaceuticals Inc. were down 5.1% in premarket trading on Thursday, the day after the company announced a public offering of 17,700,000 shares at $8.50 per share. The stock ...
PLYMOUTH MEETING, Pa., Jan. 20, 2021 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat...
PLYMOUTH MEETING, Pa., Jan. 20, 2021 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat...
The biotech company's COVID-19 vaccine candidate may not be near the finish line, but that doesn't mean investors should count it out just yet.
Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a dea...
PLYMOUTH MEETING, Pa., Jan. 6, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from...
When will INO stock finally turn a corner? That's a question on some investor's minds, and recent data suggests a turnaround might be afoot.
Shares of Inovio Pharmaceuticals Inc (NASDAQ: INO), which is developing a DNA vaccine against the novel coronavirus, were advancing Monday. What Happened: Plymouth Meeting, Pennsylvania-based ...
Shares of Inovio Pharmaceuticals Inc. were up 4.5% in premarket trading on Monday after the company announced a licensing deal with Advaccine Biopharmaceuticals Suzhou Co. Ltd. for its COVID-1...
Investors in fast-moving biotechs made out like bandits.
This coronavirus vaccine drugmaker has already made many of its early investors rich, but its valuation is still dirt cheap.
Analysts have very different takes on the early-stage results for the company's COVID-19 vaccine candidate.
We discuss six biotech/drug stocks, NVAX, VXRT, MRNA, TBIO, INO and BNTX that have more than doubled in 2020 on the back of their progress in coronavirus vaccine development.
Inovio Pharmaceuticals Inc (NASDAQ: INO) shares were trading higher Thursday after the company released positive Phase 1 data on to its COVID-19 DNA vaccine candidate. What Happened: On Wednes...
PLYMOUTH MEETING, Pa., Dec. 24, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people fro...
These stocks could shine next year, assuming they don't stumble beforehand.
Investors need to pay close attention to Inovio Pharmaceuticals (INO) stock based on the movements in the options market lately.
Investors favored coronavirus vaccine work, late-stage trial victories, and genetic sequencing.
PLYMOUTH MEETING, Pa., Dec. 9, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from...
Shares of Inovio Pharmaceuticals Inc. gained 0.6% in premarket trading on Monday after the company said it started dosing participants in a Phase 2 clinical trial for its experimental COVID-19...
The company taps another partner to help make its coronavirus vaccine when, and if, it's approved.
Inovio Pharmaceuticals Inc (NASDAQ: INO), which is developing a DNA vaccine against SARS-CoV-2, issued an update on its vaccine program Thursday, sending the stock higher. What Happened: The ...
While INO stock has boasted a banner year, Inovio appears no closer to a Covid-19 vaccine than any of the other 150 contenders. The post Just Say No to Inovio Pharmaceuticals Stock appeared fi...
Now that companies such as Pfizer, Moderna and AstraZeneca have emerged with viable vaccines against Covid-19, the hype around many pharmaceutical stocks is fading. Here are four stocks invest...
A potential coronavirus vaccine isn't the only promising pipeline candidate for this small-cap biotech.
If you're thinking that INO stock is just a wager on a Covid-19 vaccine candidate, think again. Inovio's pipeline is robust and diverse.
About INO
Inovio Pharmaceuticals, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated pre... [Read more...]
| Industry Biotechnology | IPO Date Feb 12, 1998 |
| CEO Jong Kim | Employees 190 |
| Stock Exchange NASDAQ | Ticker Symbol INO |
Financial Performance
In 2019, INO's revenue was $4.11 million, a decrease of -86.51% compared to the previous year's $30.48 million. Losses were -$119.36 million, 23.1% more than in 2018.
Analyst Forecasts
According to 8 analysts, the average rating for INO stock is "Hold." The 12-month stock price forecast is 15.13, which is an increase of 36.31% from the latest price.